# ImmunityBio, Inc.: financial statements, quarterly

IBRX · Nasdaq · CIK 1326110 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ibrx.md) · [Financials](/companies/ibrx/financials.md) · [Filings](/companies/ibrx/filings.md) · [Insiders](/companies/ibrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ibrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001326110-24-000111.md) | [0.1 d](/filings/0001326110-26-000030.md) | [0.0](/filings/0001326110-25-000071.md) | [1.0](/filings/0001326110-25-000114.md) | [6.1](/filings/0001326110-25-000139.md) | [7.6 d](/filings/0001326110-26-000030.md) | [16.5](/filings/0001326110-26-000059.md) | [26.4](/filings/0001326110-26-000079.md) | [32.1](/filings/0001326110-25-000139.md) | [38.3 d](/filings/0001326110-26-000030.md) | [44.2](/filings/0001326110-26-000059.md) | [51.2](/filings/0001326110-26-000079.md) |
| Cost of revenue | $m | [0.0](/filings/0001326110-24-000111.md) | [0.0 d](/filings/0001326110-26-000030.md) | [0.0](/filings/0001326110-25-000071.md) | [0.0](/filings/0001326110-25-000114.md) | [0.0](/filings/0001326110-25-000139.md) | [0.0 d](/filings/0001326110-26-000030.md) | [0.1](/filings/0001326110-26-000059.md) | [0.1](/filings/0001326110-26-000079.md) | [0.2](/filings/0001326110-25-000139.md) | [0.4 d](/filings/0001326110-26-000030.md) | [0.2](/filings/0001326110-26-000059.md) | [0.3](/filings/0001326110-26-000079.md) |
| Research and development | $m | [48.4](/filings/0001326110-24-000111.md) | [51.5 d](/filings/0001326110-25-000033.md) | [53.4](/filings/0001326110-24-000064.md) | [51.1](/filings/0001326110-24-000103.md) | [50.4](/filings/0001326110-24-000111.md) | [35.2 d](/filings/0001326110-25-000033.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [31.8](/filings/0001326110-24-000111.md) | [33.1 d](/filings/0001326110-25-000033.md) | [41.9](/filings/0001326110-24-000064.md) | [49.3](/filings/0001326110-24-000103.md) | [35.9](/filings/0001326110-24-000111.md) | [41.7 d](/filings/0001326110-25-000033.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(80.1)](/filings/0001326110-24-000111.md) | [(85.4) d](/filings/0001326110-26-000030.md) | [(95.2)](/filings/0001326110-25-000071.md) | [(99.3)](/filings/0001326110-25-000114.md) | [(80.3)](/filings/0001326110-25-000139.md) | [(69.4) d](/filings/0001326110-26-000030.md) | [(64.4)](/filings/0001326110-26-000059.md) | [(71.3)](/filings/0001326110-26-000079.md) | [(55.6)](/filings/0001326110-25-000139.md) | [(64.7) d](/filings/0001326110-26-000030.md) | [(69.8)](/filings/0001326110-26-000059.md) | [(61.7)](/filings/0001326110-26-000079.md) |
| Interest expense | $m | [35.0](/filings/0001326110-24-000111.md) | [31.8 d](/filings/0001326110-26-000030.md) | [29.5](/filings/0001326110-25-000071.md) | [29.8](/filings/0001326110-25-000114.md) | [29.3](/filings/0001326110-25-000139.md) | [26.0 d](/filings/0001326110-26-000030.md) | [15.3](/filings/0001326110-25-000071.md) | [15.5](/filings/0001326110-25-000114.md) | [15.3](/filings/0001326110-25-000139.md) | [14.8 d](/filings/0001326110-26-000030.md) | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001326110-24-000111.md) | [(0.0) d](/filings/0001326110-26-000030.md) | [0.0](/filings/0001326110-25-000071.md) | [0.0](/filings/0001326110-25-000114.md) | [0.0](/filings/0001326110-25-000139.md) | [0.0 d](/filings/0001326110-26-000030.md) | [(0.2)](/filings/0001326110-26-000059.md) | [0.3](/filings/0001326110-26-000079.md) | [(0.0)](/filings/0001326110-25-000139.md) | [(0.1) d](/filings/0001326110-26-000030.md) | [0.0](/filings/0001326110-26-000059.md) | [0.0](/filings/0001326110-26-000079.md) |
| Net income | $m | [(95.6)](/filings/0001326110-24-000111.md) | [(233) d](/filings/0001326110-26-000030.md) | [(134)](/filings/0001326110-25-000071.md) | [(135)](/filings/0001326110-25-000114.md) | [(85.7)](/filings/0001326110-25-000139.md) | [(59.2) d](/filings/0001326110-26-000030.md) | [(130)](/filings/0001326110-26-000059.md) | [(92.6)](/filings/0001326110-26-000079.md) | [(67.3)](/filings/0001326110-25-000139.md) | [(61.9) d](/filings/0001326110-26-000030.md) | [(633)](/filings/0001326110-26-000059.md) | [(230)](/filings/0001326110-26-000079.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0001326110-24-000111.md) | not reported | [(0.20)](/filings/0001326110-25-000071.md) | [(0.20)](/filings/0001326110-25-000114.md) | [(0.14)](/filings/0001326110-25-000139.md) | not reported | [(0.15)](/filings/0001326110-26-000059.md) | [(0.10)](/filings/0001326110-26-000079.md) | [(0.07)](/filings/0001326110-25-000139.md) | not reported | [(0.62)](/filings/0001326110-26-000059.md) | [(0.22)](/filings/0001326110-26-000079.md) |
| Basic EPS | $ per share | [(0.19)](/filings/0001326110-24-000111.md) | not reported | [(0.20)](/filings/0001326110-25-000071.md) | [(0.20)](/filings/0001326110-25-000114.md) | [(0.12)](/filings/0001326110-25-000139.md) | not reported | [(0.15)](/filings/0001326110-26-000059.md) | [(0.10)](/filings/0001326110-26-000079.md) | [(0.07)](/filings/0001326110-25-000139.md) | not reported | [(0.62)](/filings/0001326110-26-000059.md) | [(0.22)](/filings/0001326110-26-000079.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [178](/filings/0001326110-24-000111.md) | [265](/filings/0001326110-26-000030.md) | [133](/filings/0001326110-25-000071.md) | [130](/filings/0001326110-25-000114.md) | [112](/filings/0001326110-25-000139.md) | [143](/filings/0001326110-26-000030.md) | [60.7](/filings/0001326110-26-000059.md) | [138](/filings/0001326110-26-000079.md) | [60.2](/filings/0001326110-25-000139.md) | [88.3](/filings/0001326110-26-000079.md) | [205](/filings/0001326110-26-000059.md) | [75.7](/filings/0001326110-26-000079.md) |
| Current assets | $m | [215](/filings/0001326110-23-000147.md) | [294](/filings/0001326110-25-000033.md) | [196](/filings/0001326110-24-000064.md) | [243](/filings/0001326110-24-000103.md) | [163](/filings/0001326110-24-000111.md) | [185](/filings/0001326110-26-000030.md) | [109](/filings/0001326110-25-000071.md) | [208](/filings/0001326110-25-000114.md) | [329](/filings/0001326110-25-000139.md) | [315](/filings/0001326110-26-000079.md) | [453](/filings/0001326110-26-000059.md) | [439](/filings/0001326110-26-000079.md) |
| Total assets | $m | [432](/filings/0001326110-23-000147.md) | [504](/filings/0001326110-25-000033.md) | [401](/filings/0001326110-24-000064.md) | [444](/filings/0001326110-24-000103.md) | [365](/filings/0001326110-24-000111.md) | [383](/filings/0001326110-26-000030.md) | [304](/filings/0001326110-25-000071.md) | [402](/filings/0001326110-25-000114.md) | [519](/filings/0001326110-25-000139.md) | [502](/filings/0001326110-26-000079.md) | [647](/filings/0001326110-26-000059.md) | [629](/filings/0001326110-26-000079.md) |
| Current liabilities | $m | [90.3](/filings/0001326110-23-000147.md) | [58.3](/filings/0001326110-25-000033.md) | [53.8](/filings/0001326110-24-000064.md) | [62.1](/filings/0001326110-24-000103.md) | [61.0](/filings/0001326110-24-000111.md) | [54.9](/filings/0001326110-26-000030.md) | [49.2](/filings/0001326110-25-000071.md) | [50.6](/filings/0001326110-25-000114.md) | [57.1](/filings/0001326110-25-000139.md) | [61.8](/filings/0001326110-26-000079.md) | [68.0](/filings/0001326110-26-000059.md) | [76.7](/filings/0001326110-26-000079.md) |
| Total liabilities | $m | [843](/filings/0001326110-23-000147.md) | [1,090](/filings/0001326110-25-000033.md) | [1,092](/filings/0001326110-24-000064.md) | [1,142](/filings/0001326110-24-000103.md) | [1,109](/filings/0001326110-24-000111.md) | [871](/filings/0001326110-26-000030.md) | [894](/filings/0001326110-25-000071.md) | [972](/filings/0001326110-25-000114.md) | [1,042](/filings/0001326110-25-000139.md) | [1,001](/filings/0001326110-26-000079.md) | [1,516](/filings/0001326110-26-000059.md) | [1,674](/filings/0001326110-26-000079.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [1.2](/filings/0001326110-26-000030.md) | not reported | not reported | [2.6](/filings/0001326110-25-000139.md) | [1.8](/filings/0001326110-26-000059.md) | [0.9](/filings/0001326110-26-000059.md) | not reported |
| Shareholders' equity | $m | [(412)](/filings/0001326110-23-000147.md) | [(587)](/filings/0001326110-25-000033.md) | [(692)](/filings/0001326110-24-000064.md) | [(698)](/filings/0001326110-24-000103.md) | [(745)](/filings/0001326110-24-000111.md) | [(489)](/filings/0001326110-26-000030.md) | [(591)](/filings/0001326110-25-000071.md) | [(571)](/filings/0001326110-25-000114.md) | [(524)](/filings/0001326110-25-000139.md) | [(500)](/filings/0001326110-26-000079.md) | [(870)](/filings/0001326110-26-000059.md) | [(1,047)](/filings/0001326110-26-000079.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(87.4) d](/filings/0001326110-24-000111.md) | [(115) d](/filings/0001326110-26-000030.md) | [(107)](/filings/0001326110-25-000071.md) | [(100) d](/filings/0001326110-25-000114.md) | [(98.8) d](/filings/0001326110-25-000139.md) | [(85.1) d](/filings/0001326110-26-000030.md) | [(85.9)](/filings/0001326110-26-000059.md) | [(79.7) d](/filings/0001326110-26-000079.md) | [(68.9) d](/filings/0001326110-25-000139.md) | [(70.4) d](/filings/0001326110-26-000030.md) | [(75.4)](/filings/0001326110-26-000059.md) | [(66.5) d](/filings/0001326110-26-000079.md) |
| Capital expenditure | $m | [5.7 d](/filings/0001326110-24-000111.md) | [8.0 d](/filings/0001326110-26-000030.md) | [1.3](/filings/0001326110-25-000071.md) | [0.7 d](/filings/0001326110-25-000114.md) | [2.8 d](/filings/0001326110-25-000139.md) | [2.1 d](/filings/0001326110-26-000030.md) | [1.1](/filings/0001326110-26-000059.md) | [1.1 d](/filings/0001326110-26-000079.md) | [0.7 d](/filings/0001326110-25-000139.md) | [0.9 d](/filings/0001326110-26-000030.md) | [1.8](/filings/0001326110-26-000059.md) | [3.5 d](/filings/0001326110-26-000079.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [400](/filings/0001326110-23-000147.md) | [428](/filings/0001326110-24-000064.md) | [437](/filings/0001326110-24-000103.md) | [498](/filings/0001326110-24-000111.md) | [673](/filings/0001326110-25-000071.md) | [687](/filings/0001326110-25-000114.md) | [698](/filings/0001326110-25-000139.md) | [853](/filings/0001326110-26-000059.md) | [888](/filings/0001326110-26-000079.md) | [947](/filings/0001326110-25-000139.md) | [1,027](/filings/0001326110-26-000059.md) | [1,050](/filings/0001326110-26-000079.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,059,836,273 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001326110-26-000079.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.